Another Allergan activist backs immediate split to CEO, chairman by Eric Sagonowsky Friday, March 1, 2019 Allergan has faced pressure to split Brent Saunders' CEO and chairman jobs, and now rebel investors are teaming up.
Hedge funder renews call for Allergan CEO-chairman split by Eric Sagonowsky Tuesday, February 5, 2019 Unhappy with Allergan's performance and outlook, hedge fund Appaloosa once again called on the company to split up its CEO and chairman jobs.
Did Allergan lose its $2.1B Kythera bet? by Carly Helfand Tuesday, November 7, 2017 Over two years ago, Bernstein analyst Ronny Gal wrote that Allergan “obviously” has “much higher expectations than we do” for chin-fat drug Kybella.
The world's best pharma market? Easy one, Allergan CEO says by Carly Helfand Monday, August 7, 2017 What’s the best pharma market in the world? According to Allergan CEO Brent Saunders, it’s medical aesthetics.
Botox, fillers steal the show as Allergan posts Q2 beats by Carly Helfand Thursday, August 3, 2017 Allergan’s catching a break this year, and it’s one that Thursday allowed it to hike its guidance for 2017.
Can Allergan's aesthetics lineup shake off 'meh' Kybella growth? by Carly Helfand Monday, July 10, 2017 Halfway through a year Allergan execs have called "pivotal" for Kybella, one analyst describes the product’s launch as “meh.”
Kybella 'Ancestors' by Beth Snyder Bulik Kybella's nomination came down to two primary reasons: a Kardashian and a clever twist.
Editors' Choice: Our Top 5 DTC ad picks for 2016 by Beth Snyder Bulik The editors and reporters of FiercePharmaMarketing got together to select our top DTC ad picks for the year. Some impressed us with creativity, while others broke new ground or proved particularly effective.
Allergan shells out $2.5B for fat-freezing tech by Eric Sagonowsky Monday, February 13, 2017 Allergan unveiled its latest “stepping-stone deal” Monday: The "fat freezing" company Zeltiq, a $2.47 billion add-on for its aesthetics business.
